Where is molly

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: Molly, also known as MDMA (3,4-methylenedioxymethamphetamine), is a synthetic psychoactive drug first synthesized in 1912 by German pharmaceutical company Merck. It gained popularity in the 1980s and 1990s as a party drug, with the DEA reporting over 1.5 million users in the United States in 2021. The drug is typically consumed in pill or powder form, with effects lasting 3-6 hours.

Key Facts

MDMA was first synthesized in 1912 by Merck pharmaceutical company
The DEA reported 1.5 million MDMA users in the United States in 2021
MDMA effects typically last 3-6 hours after consumption
Ecstasy pills seized in 2020 contained an average of 125mg MDMA according to UNODC
Phase 3 clinical trials for MDMA-assisted therapy began in 2021 for PTSD treatment

Overview

Molly, the street name for MDMA (3,4-methylenedioxymethamphetamine), is a synthetic psychoactive substance with stimulant and mild hallucinogenic properties. First synthesized in 1912 by German pharmaceutical company Merck, it was initially investigated for potential medical applications but never marketed. The drug remained largely obscure until the 1970s when psychotherapists began exploring its potential for enhancing therapeutic processes, particularly in couples counseling and trauma therapy.

The recreational use of MDMA exploded in the 1980s and 1990s, particularly within rave and electronic dance music scenes. The U.S. Drug Enforcement Administration (DEA) placed MDMA on Schedule I of the Controlled Substances Act in 1985, classifying it as having high abuse potential and no accepted medical use. Despite this classification, research into therapeutic applications has continued, with the Multidisciplinary Association for Psychedelic Studies (MAPS) leading clinical trials since the 2000s.

How It Works

MDMA primarily affects three key neurotransmitter systems in the brain, producing its characteristic effects of euphoria, emotional openness, and increased energy.

Serotonin Release: MDMA causes massive release of serotonin, with studies showing 300-400% increases in extracellular serotonin levels. This neurotransmitter regulates mood, appetite, and sleep, explaining the profound feelings of well-being and emotional connection users experience. The serotonin depletion that follows contributes to the "Tuesday blues" or post-use depression many report.
Dopamine and Norepinephrine Effects: The drug also increases dopamine by approximately 150-200% and norepinephrine by similar percentages. Dopamine enhances pleasure and reward sensations, while norepinephrine increases heart rate, blood pressure, and body temperature. These combined effects create the energetic, alert state characteristic of MDMA use.
Oxytocin Release: MDMA stimulates oxytocin secretion, sometimes called the "love hormone," which promotes feelings of trust, empathy, and social bonding. Research shows oxytocin levels can increase by 200-300% following MDMA administration. This explains why users often report enhanced emotional intimacy and reduced social anxiety during the experience.
Duration and Metabolism: Effects typically begin 30-45 minutes after ingestion and last 3-6 hours. The liver metabolizes MDMA primarily through CYP2D6 enzymes, with elimination half-life ranging from 6-10 hours. Regular use can lead to tolerance, with some users requiring 50-100% higher doses to achieve the same effects within just a few uses.

Key Comparisons

Feature	MDMA (Molly/Ecstasy)	Other Common Party Drugs
Primary Effects	Euphoria, empathy, energy (3-6 hour duration)	Ketamine: dissociation, sedation (45-90 min); Cocaine: stimulation, confidence (15-30 min)
Typical Dose	75-125mg pure MDMA (Ecstasy pills average 125mg)	LSD: 50-200 micrograms; Methamphetamine: 10-30mg; Cocaine: 20-100mg
Addiction Potential	Moderate (DEA Schedule I)	Cocaine/Meth: High (Schedule II); Ketamine: Moderate (Schedule III); LSD: Low (Schedule I)
Medical Research Status	Phase 3 trials for PTSD (MAPS, 2021-present)	Ketamine: FDA-approved for depression (2019); Psilocybin: Phase 2 trials for depression
Global Prevalence	Estimated 20 million users worldwide (UNODC 2022)	Cocaine: 21 million; Amphetamines: 34 million; Cannabis: 200+ million

Why It Matters

Therapeutic Breakthrough: MDMA-assisted therapy has shown remarkable results in clinical trials, with 67% of participants no longer meeting PTSD criteria after three sessions in Phase 2 trials. The FDA granted Breakthrough Therapy designation in 2017, and Phase 3 trials completed in 2021 showed similar efficacy rates. This could revolutionize trauma treatment if approved.
Public Health Impact: According to the 2021 National Survey on Drug Use and Health, approximately 2.6 million Americans reported using MDMA in the past year. Emergency department visits involving MDMA increased by 123% between 2011 and 2018, highlighting significant public health concerns. The European Monitoring Centre for Drugs and Drug Addiction reports MDMA-related deaths have doubled in Europe since 2014.
Cultural Significance: MDMA played a crucial role in the development of rave culture and electronic dance music scenes worldwide. The drug's empathy-enhancing effects influenced not just music but also social movements, with some researchers suggesting it contributed to increased LGBTQ+ acceptance in certain communities during the 1990s.

Looking forward, the potential FDA approval of MDMA-assisted therapy for PTSD in 2024 could mark a significant shift in how society views this controversial substance. Simultaneously, harm reduction approaches are becoming more widespread, with organizations like DanceSafe providing drug checking services at events. The future of MDMA will likely involve balancing its demonstrated medical benefits against ongoing recreational abuse concerns, requiring nuanced policies that recognize both its therapeutic potential and risks.